Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2891

1.

The progestin norethindrone affects sex differentiation and alters transcriptional profiles of genes along the hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal axes in juvenile zebrafish Dario renio.

Hou LP, Chen H, Tian CE, Shi WJ, Liang Y, Wu RR, Fang XW, Zhang CP, Liang YQ, Xie L.

Aquat Toxicol. 2018 Aug;201:31-39. doi: 10.1016/j.aquatox.2018.05.019. Epub 2018 May 28.

2.

Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.

Maritz MF, Ray RM, Bick AJ, Tomasicchio M, Woodland JG, Govender Y, Avenant C, Hapgood JP.

PLoS One. 2018 Apr 26;13(4):e0196043. doi: 10.1371/journal.pone.0196043. eCollection 2018.

3.

Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.

Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta AD.

J Pediatr Adolesc Gynecol. 2018 Aug;31(4):376-381. doi: 10.1016/j.jpag.2018.03.004. Epub 2018 Mar 15.

PMID:
29551430
4.

Shifting from Oral Contraceptives to Norethisterone Acetate, or Vice Versa, because of Drug Intolerance: Does the Change Benefit Women with Endometriosis?

Vercellini P, Ottolini F, Frattaruolo MP, Buggio L, Roberto A, Somigliana E.

Gynecol Obstet Invest. 2018;83(3):275-284. doi: 10.1159/000486335. Epub 2018 Feb 27.

PMID:
29486468
5.

Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study.

Scala C, Leone Roberti Maggiore U, Barra F, Venturini PL, Ferrero S.

Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:89-94. doi: 10.1016/j.ejogrb.2018.01.022. Epub 2018 Feb 3.

PMID:
29408753
6.

The progestin norethisterone affects thyroid hormone-dependent metamorphosis of Xenopus laevis tadpoles at environmentally relevant concentrations.

Lorenz C, Krüger A, Schöning V, Lutz I.

Ecotoxicol Environ Saf. 2018 Apr 15;150:86-95. doi: 10.1016/j.ecoenv.2017.12.022. Epub 2017 Dec 19.

PMID:
29268119
7.

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):497-504. doi: 10.1210/jc.2017-01875.

PMID:
29216361
8.

Norethisterone enanthate-induced cerebral venous sinus thrombosis (CVST).

Bahall M, Santlal M.

BMJ Case Rep. 2017 Nov 14;2017. pii: bcr-2017-222418. doi: 10.1136/bcr-2017-222418.

9.

Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.

Hasegawa S, Matsui T, Hane Y, Abe J, Hatahira H, Motooka Y, Sasaoka S, Fukuda A, Naganuma M, Hirade K, Takahashi Y, Kinosada Y, Nakamura M.

PLoS One. 2017 Jul 21;12(7):e0182045. doi: 10.1371/journal.pone.0182045. eCollection 2017.

10.

The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: A xenograft model.

Zhao Y, Ruan X, Wang H, Li X, Gu M, Wang L, Li Y, Seeger H, Mueck AO.

Maturitas. 2017 Aug;102:26-33. doi: 10.1016/j.maturitas.2017.05.007. Epub 2017 May 13.

PMID:
28610679
11.

Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.

Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, Kintu K, Nair G, Chappell C, Kiweewa FM, Kabwigu S, Naidoo L, Jeenarain N, Marzinke M, Soto-Torres L, Brown ER, Baeten JM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):e47-e51. doi: 10.1097/QAI.0000000000001455.

PMID:
28542081
12.

The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis.

Grandi G, Mueller MD, Bersinger NA, Facchinetti F, McKinnon BD.

Gynecol Endocrinol. 2017 Sep;33(9):712-715. doi: 10.1080/09513590.2017.1314458. Epub 2017 Apr 17.

PMID:
28412861
13.

Clinical pharmacokinetic interactions between lamotrigine and hormonal contraceptives in bipolar I disorder.

Sawagashira R, Fujii Y, Kusumi I.

Psychiatry Clin Neurosci. 2017 Apr;71(4):290. doi: 10.1111/pcn.12512. Epub 2017 Mar 16. No abstract available.

14.

Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.

Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E.

Andrology. 2017 May;5(3):516-526. doi: 10.1111/andr.12328. Epub 2017 Feb 11.

15.

Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills.

Casper RF.

Fertil Steril. 2017 Mar;107(3):533-536. doi: 10.1016/j.fertnstert.2017.01.003. Epub 2017 Feb 2. Review.

PMID:
28162779
16.

Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate.

Brady PC, Missmer SA, Laufer MR.

J Pediatr Adolesc Gynecol. 2017 Jun;30(3):422-424. doi: 10.1016/j.jpag.2016.12.002. Epub 2016 Dec 23.

PMID:
28024920
17.

Injectable contraception: updates and innovation.

Schivone G, Dorflinger L, Halpern V.

Curr Opin Obstet Gynecol. 2016 Dec;28(6):504-509. Review.

PMID:
27787287
18.

Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries.

Román M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1464-1473. Epub 2016 Jul 26.

19.

Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men.

Behre HM, Zitzmann M, Anderson RA, Handelsman DJ, Lestari SW, McLachlan RI, Meriggiola MC, Misro MM, Noe G, Wu FC, Festin MP, Habib NA, Vogelsong KM, Callahan MM, Linton KA, Colvard DS.

J Clin Endocrinol Metab. 2016 Dec;101(12):4779-4788. Epub 2016 Oct 27.

PMID:
27788052
20.

Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial.

Harada T, Momoeda M.

Fertil Steril. 2016 Dec;106(7):1807-1814. doi: 10.1016/j.fertnstert.2016.08.051. Epub 2016 Oct 4.

PMID:
27717552

Supplemental Content

Loading ...
Support Center